📊 GTBP Key Takeaways
Is GT Biopharma, Inc. (GTBP) a Good Investment?
GT Biopharma is a pre-revenue pharmaceutical company with zero commercial sales and mounting operational losses (-$2.8M), coupled with negative operating cash flow (-$2.5M) that limits runway to approximately 3-4 quarters at current burn rates. The company destroys shareholder value with negative ROE (-37.4%) and ROA (-34.9%), with only a strong liquidity position (4.14x current ratio) as a buffer.
GT Biopharma is a pre-revenue biotech with sustained operating losses and extremely negative returns on equity and assets. Cash (~$6.8M) is well below annual operating cash burn (~$12.9M), implying a near-term financing need and dilution risk. While the balance sheet is debt-free with a solid current ratio, fundamentals show no visibility to revenue or profitability.
Why Buy GT Biopharma, Inc. Stock? GTBP Key Strengths
- Strong liquidity with 4.14x current ratio and $8.9M cash equivalents
- No long-term debt and minimal leverage (0.00x Debt/Equity) reduces financial risk
- Positive stockholders' equity of $7.6M provides equity cushion
- Debt-free capital structure with low liabilities
- Solid liquidity (current/quick ratio 3.5x)
- Net loss improved YoY
GTBP Stock Risks: GT Biopharma, Inc. Investment Risks
- Zero revenue - no commercial product generating sales
- Negative cash flow from operations at $2.5M annually with approximately 3-4 quarter runway
- Severely negative profitability metrics (ROE -37.4%, ROA -34.9%) indicate value destruction
- No insider buying activity suggests lack of confidence from management
- Pre-revenue biotech status with unproven commercialization capability
- Zero revenue and no gross profit
- High cash burn relative to cash balance (short runway)
- Likely dilution/going-concern risk to fund operations
Key Metrics to Watch
- Revenue generation and commercial product launch timeline
- Quarterly cash burn rate and cash runway adequacy
- R&D spending efficiency and pipeline clinical trial progress
- Insider trading activity and capital raise announcements
- Operating cash flow (cash burn)
- Cash & equivalents (runway in months)
GT Biopharma, Inc. (GTBP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.14x current ratio provides a solid financial cushion.
GTBP Profit Margin, ROE & Profitability Analysis
GTBP vs Healthcare Sector: How GT Biopharma, Inc. Compares
How GT Biopharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GT Biopharma, Inc. Stock Overvalued? GTBP Valuation Analysis 2026
Based on fundamental analysis, GT Biopharma, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GT Biopharma, Inc. Balance Sheet: GTBP Debt, Cash & Liquidity
GTBP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: GT Biopharma, Inc.'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-6.94 indicates the company is currently unprofitable.
GTBP Revenue Growth, EPS Growth & YoY Performance
GTBP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | N/A | $1.9M | N/A |
| Q2 2021 | N/A | $1.6M | N/A |
| Q1 2021 | N/A | -$1.7M | N/A |
| Q1 2020 | N/A | -$1.7M | $-0.02 |
| Q1 2019 | N/A | -$4.5M | $-0.09 |
| Q2 2018 | N/A | -$2.5M | $335,450.00 |
| Q1 2018 | N/A | -$5.1M | $-0.20 |
| Q3 2017 | N/A | -$3.6M | $-8.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GT Biopharma, Inc. Dividends, Buybacks & Capital Allocation
GTBP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for GT Biopharma, Inc. (CIK: 0000109657)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GTBP
What is the AI rating for GTBP?
GT Biopharma, Inc. (GTBP) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 83% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GTBP's key strengths?
Claude: Strong liquidity with 4.14x current ratio and $8.9M cash equivalents. No long-term debt and minimal leverage (0.00x Debt/Equity) reduces financial risk. ChatGPT: Debt-free capital structure with low liabilities. Solid liquidity (current/quick ratio 3.5x).
What are the risks of investing in GTBP?
Claude: Zero revenue - no commercial product generating sales. Negative cash flow from operations at $2.5M annually with approximately 3-4 quarter runway. ChatGPT: Zero revenue and no gross profit. High cash burn relative to cash balance (short runway).
What is GTBP's revenue and growth?
GT Biopharma, Inc. reported revenue of $0.0.
Does GTBP pay dividends?
GT Biopharma, Inc. pays dividends, with $0.2M distributed to shareholders in the trailing twelve months.
Where can I find GTBP SEC filings?
Official SEC filings for GT Biopharma, Inc. (CIK: 0000109657) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GTBP's EPS?
GT Biopharma, Inc. has a diluted EPS of $-0.11.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GTBP a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, GT Biopharma, Inc. has a STRONG SELL rating with 83% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GTBP stock overvalued or undervalued?
Valuation metrics for GTBP: ROE of -37.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GTBP stock in 2026?
Our dual AI analysis gives GT Biopharma, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GTBP's free cash flow?
GT Biopharma, Inc.'s operating cash flow is $-2.5M, with capital expenditures of $0.0.
How does GTBP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -37.4% (avg: 15%), current ratio 4.14 (avg: 2).